Logo image
EpCAM immunotherapy versus specific targeted delivery of drugs
Journal article   Open access   Peer reviewed

EpCAM immunotherapy versus specific targeted delivery of drugs

J. Macdonald, J. Henri, K. Roy, E. Hays, M. Bauer, R. Veedu, N. Pouliot and S. Shigdar
Cancers, Vol.10(1), E19
2018
pdf
EpCAM Immunotherapy versus Specific Targeted.pdfDownloadView
Published (Version of Record) Open Access
url
Free to Read *No subscription requiredView

Abstract

The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Metrics

79 File views/ downloads
39 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
2 Chemistry
2.145 Biosensors
2.145.243 Nanobiosensors
Web Of Science research areas
Oncology
ESI research areas
Clinical Medicine
Logo image